Compare · ONCY vs PBYI
ONCY vs PBYI
Side-by-side comparison of Oncolytics Biotech Inc. (ONCY) and Puma Biotechnology Inc (PBYI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ONCY and PBYI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- PBYI is the larger of the two at $543.0M, about 7.6x ONCY ($71.8M).
- Over the past year, ONCY is down 57.7% and PBYI is up 79.3% - PBYI leads by 137.0 points.
- ONCY has been more active in the news (12 items in the past 4 weeks vs 2 for PBYI).
- PBYI has more recent analyst coverage (4 ratings vs 2 for ONCY).
- Company
- Oncolytics Biotech Inc.
- Puma Biotechnology Inc
- Price
- $0.50-9.19%
- $9.82-6.61%
- Market cap
- $71.8M
- $543.0M
- 1M return
- -35.19%
- +3.20%
- 1Y return
- -57.70%
- +79.29%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- News (4w)
- 12
- 2
- Recent ratings
- 2
- 4
Oncolytics Biotech Inc.
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. Its lead product is pelareorep, an immuno-oncology viral-agent for the treatment of solid tumors and hematological malignancies. The company has collaboration agreements with Merck KGaA and Pfizer Inc. to co-develop pelareorep in combination with paclitaxel and avelumab, a human anti-PD-L1 antibody for the treatment of hormone-receptor positive, human epidermal growth factor 2-negative metastatic breast cancer; and PrECOG LLC. The company was incorporated in 1998 and is headquartered in Calgary, Canada.
Puma Biotechnology Inc
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.
Latest ONCY
- SEC Form 8-K filed by Oncolytics Biotech Inc.
- Oncolytics Biotech® Provides Update on GOBLET Study Clinical Data and Final PanCAN Grant Payment
- Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda
- SEC Form 8-K filed by Oncolytics Biotech Inc.
- Oncolytics Biotech® Secures Patent Protection to Late 2040s and Provides Intellectual Property Portfolio Update
- SEC Form DEFA14A filed by Oncolytics Biotech Inc.
- SEC Form DEF 14A filed by Oncolytics Biotech Inc.
- Oncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Oncolytics Biotech® Announces Publication Demonstrating Pelareorep Creates Immune Responses in Liver Cancer That Make Tumors Susceptible to Immunotherapy
- Oncolytics Biotech Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest PBYI
- Amendment: SEC Form SCHEDULE 13D/A filed by Puma Biotechnology Inc
- Puma Biotechnology Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
- Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
- Director Wilson Troy Edward sold $45,500 worth of shares (5,000 units at $9.10) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 54,750 units (SEC Form 4)
- Director Cesano Alessandra exercised 50,000 shares at a strike of $2.93 and sold $566,994 worth of shares (62,150 units at $9.12) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 56,700 units (SEC Form 4)
- Puma Biotechnology to Present at H.C. Wainwright’s 28th Annual Global Investment Conference
- Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
- SEC Form 10-Q filed by Puma Biotechnology Inc
- Puma Biotechnology Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Puma Biotechnology Reports Second Quarter 2026 Financial Results